Amorphization under fracture surface in hydrogen-charged and low- temperature tensile-tested austenitic stainless steel

The microstructure just below the fracture surface in hydrogen-charged stable austenitic SUS 316L stainless steel, which was subjected to a low strain rate tensile test at −70°C, was studied by a combination of the focused-ion-beam method and transmission electron microscopy. An amorphous region with a chemical composition almost identical to that of the polycrystalline region was found under the lath-like structure on the fracture surface, although no deterioration of tensile properties by hydrogen appeared. In the amorphous region, band-like regions with wavy contrasts were observed, which were often accompanied by cracks at the boundaries. The presence of the amorphous region with band-like regions implies that amorphization occurred due to high-density vacancies accompanied by agglomerations of excess vacancies in the hydrogen-charged SUS 316L stainless steel that was tensile-tested at low temperatures

International Guillain-Barré Syndrome Outcome Study (IGOS): protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome

Guillain-Barré syndrome (GBS) is an acute polyradiculoneuropathy with a highly variable clinical presentation, course, and outcome. The factors that determine the clinical variation of GBS are poorly understood which complicates the care and treatment of individual patients. The protocol of the ongoing International GBS Outcome Study (IGOS), a prospective, observational, multi-centre cohort study that aims to identify the clinical and biological determinants and predictors of disease onset, subtype, course and outcome of GBS is presented here. Patients fulfilling the diagnostic criteria for GBS, regardless of age, disease severity, variant forms, or treatment, can participate if included within two weeks after onset of weakness. Information about demography, preceding infections, clinical features, diagnostic findings, treatment, course and outcome is collected. In addition, cerebrospinal fluid and serial blood samples for serum and DNA is collected at standard time points. The original aim was to include at least 1000 patients with a follow-up of 1-3 years. Data are collected via a web-based data entry system and stored anonymously. IGOS started in May 2012 and by January 2017 included more than 1400 participants from 143 active centres in 19 countries across 5 continents. The IGOS data/biobank is available for research projects conducted by expertise groups focusing on specific topics including epidemiology, diagnostic criteria, clinimetrics, electrophysiology, antecedent events, antibodies, genetics, prognostic modelling, treatment effects and long-term outcome of GBS. The IGOS will help to standardize the international collection of data and biosamples for future research of GBS. ClinicalTrials.gov Identifier: NCT01582763